Remember when every conversation about biotech felt like the future was arriving next Tuesday? The pandemic years turned mRNA into dinner-table vocabulary, and money followed the excitement. Then the mood shifted. Rates went up, IPO windows closed, and the sector that had been everyone’s favorite story became the sector everyone stopped talking about.
Now look at the headlines. Crunchbase News reports that biotech startup investment held steady even as AI funding surged. North American startup funding shattered records in the first half of 2026, driven by AI. In Europe, Tech Times reports deal counts at a six-year low while AI absorbs 60 percent of the funding. Emerging markets VC is rebounding on a China tech surge. And BioPharma Dive notes that a biotech funding gap is widening despite the broader rebound in VC investment.
I write about AI agents for people who don’t build them, so my instinct is to ask what these numbers actually tell us about how money makes decisions. And I think the answer is more interesting than “AI is winning.”
Steady is not the same as stalled
“Held steady” sounds like faint praise. In a period where one category is pulling in record sums and swallowing most of a continent’s funding, holding steady is a real signal. It means biotech investors did not panic-rotate into the hot thing. It means the checks kept getting written at roughly the same pace, by people who understand that a drug program does not care what’s trending.
Compare that to what the European numbers describe. A six-year low in deal count, with AI taking 60 percent of the money. That’s not a growing pie shared more widely. That’s a narrower pie with one very large slice. Fewer companies are getting funded, and the ones that do are increasingly in a single category.
Why AI absorbs money so fast
Here is the part that helps if you’re new to this. AI companies, especially the ones building models and agents, have a spending profile that soaks up capital almost immediately. Compute, data, and specialist salaries are expensive from day one. A team of twenty can plausibly need enormous funding, and that money converts into a visible product quickly. You can demo an agent. You can show it booking a meeting, drafting a report, answering a customer.
Biotech runs on a different clock. A therapeutic candidate moves through preclinical work, then phases of human trials, then regulators. Years pass between the investment and the answer. There is no demo. There’s a data readout, and it either works or it doesn’t.
Both models can produce enormous returns. Only one of them produces something you can put in a pitch deck this quarter. That asymmetry explains a lot about where attention goes, and attention tends to drag money behind it.
What the widening gap actually means
BioPharma Dive’s framing is the one worth sitting with. A funding gap widening during a rebound means the recovery is uneven. Some biotech companies are doing fine. Others are being left behind while overall numbers look healthy. Averages hide that. “Held steady” at the sector level can coexist with individual companies struggling to raise a follow-on round.
This matters for anyone trying to read tech news without a finance background. Aggregate funding figures describe a distribution, not a typical experience. When you see a record-breaking half-year, ask which companies made that record and which ones the record ignored.
The AI-and-biotech overlap
There’s a wrinkle worth flagging. The line between “AI company” and “biotech company” is getting blurry. Plenty of drug discovery work now runs on machine learning, and plenty of AI agents are being pointed at scientific literature, lab automation, and trial design. How a given startup gets categorized may depend as much on how it describes itself as on what it does.
So some of the AI surge may be biotech wearing a different label, and some of the steady biotech number may include companies that would happily call themselves AI shops if it helped them raise. Category boundaries are marketing decisions as much as technical ones.
My take
Concentration is the thing I’d watch. When 60 percent of a region’s funding goes to one category and deal counts fall to a six-year low, the ecosystem gets less varied. Fewer bets, in fewer areas, from investors reading the same headlines. That’s a fragile setup regardless of whether AI delivers.
Biotech holding steady through this is, in that light, a small piece of good news. It suggests there’s still capital that operates on decade-long timelines and doesn’t need a quarterly demo. The AI agents I write about will get better and more useful. Some of them will help with drug discovery. But that work still needs patient money behind it, and patient money is exactly what surges tend to crowd out.
🕒 Published: